DARE
Daré Bioscience, Inc. NASDAQ Listed Apr 10, 2014$2.08
-0.48%
vs $2.09
Mkt Cap $232.5M
52w Low $1.30
39.6% of range
52w High $3.27
50d MA $2.27
200d MA $1.99
P/E (TTM)
-2.0x
EV/EBITDA
—
P/B
81.9x
Debt/Equity
934.4x
ROE
-471.4%
P/FCF
-0.0x
RSI (14)
54.50
ATR (14)
$0.13
Beta
0.90
50d MA
$2.27
200d MA
$1.99
Avg Volume
187.3K
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
3655 Nobel Drive · San Diego, CA 92122 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.24 | -0.02 | +91.7% | 1.51 | +2.6% | +2.6% | +18.1% | -0.5% | +4.4% | -8.4% | — |
| Nov 13, 2025 | AMC | -0.33 | -0.28 | +15.2% | 1.89 | +2.6% | -1.6% | -2.7% | -1.7% | -3.9% | -4.7% | — |
| Aug 14, 2025 | AMC | -0.55 | -0.45 | +18.2% | 2.07 | +5.8% | +6.3% | -4.1% | -4.3% | +2.0% | +1.9% | — |
| May 13, 2025 | AMC | -0.63 | -0.50 | +20.6% | 2.89 | -0.3% | +0.0% | -0.3% | +0.3% | +1.0% | -1.0% | — |
| Mar 31, 2025 | AMC | -0.66 | -0.64 | +3.0% | 2.89 | -0.3% | +0.3% | +0.3% | +0.7% | -1.0% | -0.3% | — |
| Nov 14, 2024 | AMC | -0.60 | -0.55 | +8.3% | 3.57 | -1.7% | -10.1% | -0.3% | -0.6% | +0.0% | +1.6% | — |
| Aug 12, 2024 | AMC | -0.57 | 1.52 | +366.7% | 3.50 | +7.7% | +20.0% | -16.7% | -0.6% | +2.6% | -2.5% | — |
| May 14, 2024 | AMC | -0.72 | -0.84 | -16.7% | 3.78 | +4.8% | +14.3% | +20.8% | +11.5% | +25.8% | -30.5% | — |
| Dec 30, 2023 | AMC | — | -0.69 | — | — | — | — | — | — | — | — | — |
| Nov 9, 2023 | AMC | -1.20 | -1.08 | +10.0% | 3.95 | +0.3% | +0.3% | +5.8% | -1.9% | +0.0% | -2.2% | — |
| Aug 10, 2023 | AMC | -1.20 | -1.20 | +0.0% | 8.58 | +2.8% | +6.1% | -2.0% | -1.1% | -0.7% | -4.3% | — |
| May 11, 2023 | AMC | -1.20 | -1.08 | +10.0% | 12.12 | -1.0% | -1.5% | +1.5% | +4.0% | -1.9% | -1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.67 | $1.73 | +3.6% | +3.0% | +1.7% | +2.3% | -0.6% | +3.4% |
| Sep 4 | Maxim Group | Upgrade | Hold → Buy | — | $2.06 | $2.16 | +4.9% | +3.4% | +0.9% | -0.9% | +1.4% | -1.4% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.89 | $2.88 | -0.3% | +0.3% | +0.3% | +0.7% | -1.0% | -0.3% |
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.18 | $3.18 | +0.0% | +0.3% | -0.3% | -6.3% | -9.1% | +17.7% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.57 | $3.51 | -1.7% | -10.1% | -0.3% | -0.6% | +0.0% | +1.6% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.62 | $3.50 | -3.3% | -3.3% | +4.3% | +7.1% | +1.3% | +6.8% |
| Aug 16 | Jones Trading | Maintains | Buy → Buy | — | $3.48 | $3.49 | +0.3% | +2.6% | -2.5% | +1.4% | +0.3% | -3.4% |
| Aug 14 | Maxim Group | Downgrade | Buy → Hold | — | $4.20 | $4.20 | +0.0% | -16.7% | -0.6% | +2.6% | -2.5% | +1.4% |
| May 15 | Brookline Capital | Upgrade | Hold → Buy | — | $3.78 | $3.96 | +4.8% | +14.3% | +20.8% | +11.5% | +25.8% | -30.5% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.78 | $3.96 | +4.8% | +14.3% | +20.8% | +11.5% | +25.8% | -30.5% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.69 | $3.84 | +4.1% | +7.3% | -5.6% | -0.3% | -1.6% | +1.4% |
| Apr 17 | Brookline Capital | Downgrade | Buy → Hold | — | $5.82 | $5.52 | -5.2% | -41.8% | +4.4% | -5.1% | +5.4% | +0.8% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.88 | $5.88 | +0.0% | +1.0% | -0.5% | -2.2% | +5.7% | -3.6% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.95 | $3.96 | +0.3% | +0.3% | +5.8% | -1.9% | +0.0% | -2.2% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.58 | $8.82 | +2.8% | +6.1% | -2.0% | -1.1% | -0.7% | -4.3% |
| Jul 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.62 | $10.67 | +0.5% | +1.0% | -2.7% | -2.9% | -1.8% | -3.6% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.99 | $11.88 | -0.9% | -1.9% | +0.9% | -0.4% | -0.5% | +0.0% |
| May 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.36 | $12.00 | -2.9% | -1.9% | -1.0% | -0.6% | -1.1% | -0.3% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.12 | $12.00 | -1.0% | -1.5% | +1.5% | +4.0% | -1.9% | -1.0% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.72 | $12.84 | +0.9% | -1.9% | -3.8% | +4.0% | -5.8% | -1.0% |
| Dec 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.16 | $11.88 | +6.5% | +0.5% | -1.5% | -1.8% | -1.6% | -1.3% |
| Dec 1 | JonesTrading | Maintains | Buy → Buy | — | $10.68 | $11.04 | +3.4% | +6.7% | -1.1% | +0.5% | -2.6% | -3.3% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.88 | $17.76 | -0.7% | +14.8% | +2.9% | -1.1% | -5.7% | -4.9% |
| Jun 30 | Roth Capital | Maintains | Buy → Buy | — | $19.68 | $23.28 | +18.3% | +15.2% | -6.9% | -10.2% | -3.8% | +23.7% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.56 | $14.76 | +8.8% | +23.9% | -0.7% | -5.8% | +9.9% | -2.1% |
| Apr 28 | Brookline Capital | Maintains | Buy → Buy | — | $12.60 | $14.88 | +18.1% | +2.4% | +1.4% | +1.8% | -1.8% | +0.9% |
| Aug 17 | Maxim Group | Maintains | Buy → Buy | — | $11.92 | $13.08 | +9.7% | +8.7% | +0.9% | -0.9% | +0.0% | +0.9% |
No insider trades available.
8-K · 7.01
! Medium
Daré Bioscience, Inc. -- 8-K 7.01: Regulation FD Disclosure
Daré Bioscience furnished a corporate presentation for investor reference, indicating management is actively communicating strategic updates to shareholders and stakeholders.
Jun 22
8-K · 5.02
!!! Very High
Daré Bioscience, Inc. -- 8-K 5.02: Executive Change
Jun 12
8-K · 2.02
!! High
Daré Bioscience, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 7.01
! Medium
Dare Bioscience, Inc. -- 8-K 7.01: Regulation FD Disclosure
Dare Bioscience updated its investor presentation, providing current corporate strategy and business information for stakeholder review on its investor relations website.
Apr 22
8-K
Dare Bioscience, Inc. -- 8-K Filing
I cannot write a meaningful analyst sentence based on this summary, as it contains only standard SEC filing boilerplate language with no substantive business information or events.
Apr 20
8-K · 5.02
!!! Very High
Dare Bioscience, Inc. -- 8-K 5.02: Executive Change
Dare Bioscience restructured its board governance to a staggered three-class director system, ensuring annual elections with three-year terms that limit shareholder influence and may entrench current management.
Apr 17
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing excerpt contains only boilerplate signature language without substantive business information about DARE's operations, financial results, or material events.
Apr 13
8-K
Unknown — 8-K Filing
Daré Bioscience launched its sildenafil cream product and maintains a pipeline of women's health solutions, offering potential revenue growth catalysts that could improve profitability and justify valuation expansion.
Mar 26
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing summary is incomplete and contains only boilerplate language without substantive business information about DARE's actual events or circumstances.
Mar 17
8-K
Dare Bioscience, Inc. -- 8-K Filing
Dare Bioscience's 8-K filing confirms its emerging growth company status, allowing the biopharmaceutical firm continued regulatory relief on disclosure and compliance requirements.
Mar 9
8-K · 7.01
! Medium
Dare Bioscience, Inc. -- 8-K 7.01: Regulation FD Disclosure
Dare Bioscience updated its corporate presentation on March 2, 2026, providing investors with refreshed information about the company's strategy and operations via its investor relations website.
Mar 2
Valuation
Market Cap
$232.5M
Enterprise Value
-$24.47B
P/E (TTM)
-2.00x
Forward P/E
—
PEG Ratio
-0.11x
P/B
81.89x
P/S
200.93x
P/FCF
-0.02x
EV/EBITDA
—
Shares Out
111.8M
Financials (TTM)
Revenue
$1.2M
Net Income
-$12.0M
EBITDA
-$9.5M
Free Cash Flow
-$10.27B
Op Cash Flow
-$9.89B
EPS Basic
$-1.20
EPS Diluted
$-1.04
EPS Forward
$-1.21
Gross Margin
5.6%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$32.5M
Total Liab.
$29.6M
Total Equity
$2.8M
Cash
$24.71B
LT Debt
$5.4M
Book Value/Sh
$0.03
Debt/Equity
934.35x
Current Ratio
1.14
Quick Ratio
1.14
Returns & Growth
ROE
-471.4%
ROA
-41.3%
ROIC
-124.5%
Rev Growth YoY
+10429.4%
EPS Growth YoY
-150.0%
Price Returns
2W
+0.5%
1M
-4.1%
3M
+15.5%
6M
+7.2%
12M
-12.9%
Technicals
52W High
$3.27
52W Low
$1.30
50d MA
$2.27
200d MA
$1.99
RSI (14)
54.50
ATR (14)
$0.13
Beta
0.90
Avg Volume
187K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$12.00
High
$12.00
Low
$12.00
Median
$12.00
Data updated apr 25, 2026 4:37am
· Source: financialmodelingprep.com